Trials / Terminated
TerminatedNCT02146846
Population Pharmacokinetics of Imatinib in CML Patients in Iran
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 170 (actual)
- Sponsor
- Kerman University of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine population Pharmacokinetics and differences and variation of pharmacokinetics parameters of Imatinib as a tyrosine kinase inhibitor in treatment of chronic myeloid leukemia patients in Iranian population.
Detailed description
patients with chronic myeloid leukemia who receive Imatinib as treatment in Iran entered in this study then population pharmacokinetics parameters is determined.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imatinib | Patients with chronic myeloid leukemia who receive Imatinib as treatment |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2014-04-01
- Completion
- 2017-07-01
- First posted
- 2014-05-26
- Last updated
- 2016-09-07
Locations
1 site across 1 country: Iran
Source: ClinicalTrials.gov record NCT02146846. Inclusion in this directory is not an endorsement.